AP Biosciences, Inc. (TPEX:6945)
Taiwan · Delayed Price · Currency is TWD 95.60
+0.30 (0.31%)
Sep 8, 2026, 12:44 PM CST
AP Biosciences Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 294.52 | 970.89 | 1,442 | 278.61 | 1,048 | 527.12 |
Short-Term Investments | 1,900 | 200 | 100 | 461.41 | 30.71 | 30 |
Cash & Short-Term Investments | 2,195 | 1,171 | 1,542 | 740.02 | 1,079 | 557.12 |
Cash Growth | 61.22% | -24.05% | 108.33% | -31.40% | 93.62% | -11.67% |
Other Receivables | 44.22 | 42.2 | 36.18 | 24.6 | 14.48 | 0.02 |
Receivables | 44.22 | 42.2 | 36.18 | 24.6 | 14.48 | 0.02 |
Prepaid Expenses | 7.28 | 8.5 | 3.63 | 1.03 | 0.85 | 6.81 |
Total Current Assets | 2,246 | 1,222 | 1,581 | 765.64 | 1,094 | 563.95 |
Property, Plant & Equipment | 96.89 | 108.94 | 109.33 | 116.41 | 3.02 | 8.87 |
Long-Term Investments | 63.06 | 28.29 | - | - | - | - |
Other Intangible Assets | 2.93 | 3.22 | 3.55 | 4.23 | 5.34 | 5.8 |
Other Long-Term Assets | 3.34 | 3.29 | 32.8 | 4.48 | 0.78 | 0.73 |
Total Assets | 2,412 | 1,365 | 1,727 | 890.76 | 1,103 | 579.35 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | 19.76 | 23.26 | 22.64 | 16.72 | 2.48 | 19.96 |
Current Portion of Leases | 11.65 | 11.65 | 11.65 | 11.65 | - | - |
Other Current Liabilities | 7.54 | 5.89 | 5.37 | 2.51 | 2.04 | 1.19 |
Total Current Liabilities | 38.95 | 40.8 | 39.67 | 30.88 | 4.52 | 21.15 |
Long-Term Leases | 42.07 | 47.86 | 59.26 | 70.43 | - | - |
Other Long-Term Liabilities | 5.62 | 5.57 | 5.46 | 5.35 | - | - |
Total Liabilities | 86.65 | 94.22 | 104.38 | 106.65 | 4.52 | 21.15 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 969.93 | 855.73 | 849.87 | 647.48 | 647.48 | 243.74 |
Additional Paid-In Capital | 1,556 | 859.15 | 1,196 | 475.92 | 739.72 | 502.1 |
Retained Earnings | -217.29 | -444.77 | -422.75 | -339.3 | -288.54 | -187.64 |
Comprehensive Income & Other | 16.98 | 1 | -0.66 | - | - | - |
Shareholders' Equity | 2,326 | 1,271 | 1,623 | 784.11 | 1,099 | 558.2 |
Total Liabilities & Equity | 2,412 | 1,365 | 1,727 | 890.76 | 1,103 | 579.35 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 53.73 | 59.51 | 70.91 | 82.08 | - | - |
Net Cash (Debt) | 2,141 | 1,111 | 1,471 | 657.94 | 1,079 | 557.12 |
Net Cash Growth | 65.19% | -24.43% | 123.54% | -39.01% | 93.62% | -11.67% |
Net Cash Per Share | 24.81 | 13.06 | 19.53 | 10.16 | 20.49 | 23.10 |
Filing Date Shares Outstanding | 96.99 | 85.57 | 84.99 | 64.75 | 64.75 | 24.37 |
Total Common Shares Outstanding | 96.99 | 85.57 | 84.99 | 64.75 | 64.75 | 24.37 |
Working Capital | 2,207 | 1,181 | 1,542 | 734.77 | 1,090 | 542.8 |
Book Value Per Share | 23.98 | 14.85 | 19.09 | 12.11 | 16.97 | 22.90 |
Tangible Book Value | 2,323 | 1,268 | 1,619 | 779.88 | 1,093 | 552.4 |
Tangible Book Value Per Share | 23.95 | 14.82 | 19.05 | 12.04 | 16.89 | 22.66 |
Machinery | 34.81 | 33.3 | 39.3 | 36.93 | 31.34 | 30.41 |
Construction In Progress | - | - | - | 28.2 | - | - |
Leasehold Improvements | 36.12 | 35.02 | 35.5 | - | 1 | 1 |